ArcticZymes Technologies launches AZscript™ Reverse Transcriptase

Tromsø, Norway, 16th December 2022 – ArcticZymes Technologies ASA (OSE: AZT) launches AZscript™ Reverse Transcriptase

ArcticZymes Technologies (AZT) today announces the launch of its new product AZscript™ Reverse Transcriptase (RT).

Launching the AZscript RT product is a natural expansion of the Company’s molecular tools portfolio. Reverse transcriptases are critical enzymes for molecular diagnostics and are used to convert RNA into DNA in a broad range of applications such as the detection of pathogenic RNA virus in diagnostic PCR workflows or the analysis of transcriptomes in Next Generation Sequencing (NGS).

By expanding the portfolio, the Company expects to see synergies with our existing products supporting RT-qPCR and RT-LAMP workflows in molecular research and diagnostics.

The global molecular tools market has seen a significant increase in demand in recent years. Being able to serve customers with a more complete enzyme offering will be an important driver for continued sales growth in the molecular tools business.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

“Today our customers are using Reverse Transcriptases from other suppliers seamlessly alongside AZT´s dsDNases and Cod UNG in their RNA workflows. The launch of AZscript™ Reverse Transcriptase will allow the Company to provide a reverse transcriptase that is optimised to work in combination with our other enzymes in customer workflows.”

For more information, please contact:

ArcticZymes Technologies
CEO, Jethro Holter                           T: +47 46 85 91 46
CFO, Børge Sørvoll                           T: +47 95 29 01 87 / E:


Learn more about AZscript™  here or contact your local Business Development Representative.